March Is Ovarian Cancer Awareness Month March 2, 2012Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: awareness, CA125, early detection, estrogen, hormone balance, hysterectomy, oestrogen, ovarian cancer, symptoms, UK
add a comment
March Is Ovarian Cancer Awareness Month
Although the majority of the 6,500 women diagnosed with ovarian cancer in the UK each year are menopausal, it is not solely confined to that group as younger women are also at risk.
The good news is that with early detection the survival rate is good with seven out of ten women treated will survive for five or more years. The bad news is that some of the symptoms are similar to those seen in more common conditions, like irritable bowel syndrome (IBS) so your doctor may find it hard to diagnose.
What Can You Do?
Awareness is key, because to help your doctor diagnose ovarian cancer you need to monitor your body and report any symptoms as soon as you spot them. Also, cervical screening tests (smear tests) will not help to detect ovarian cancer so don’t rely on getting a clear result from that indicating you are clear of ovarian cancer.
Women need to learn to recognise the symptoms and go to see their doctor as soon as possible if they have any of the following consistently over a month and they don’t go away:
Persistent pelvic or abdominal pain
Increased abdominal size/persistent bloating (not the normal blow up around a period that comes and goes)
Difficulty eating or feeling full quickly
Urinary symptoms such as more frequent or urgent need to pee
Those are the most common symptoms, but sometimes there can be other such as:
Changes in bowel habit
Extreme fatigue (feeling very tired)
Unexplained weight loss
If you regularly experience any of these symptoms and they are not normal for you then please don’t hesitate but go and see your doctor. They may be nothing, but it is important to be checked out. It will help your doctor if you also keep a note of your symptoms such as when they occur and if related to specific events. They will also want to know if there is any history of ovarian or breast cancer in your immediate family.
What Treatment Is Available?
First your doctor may suggest a CA125 blood test and, depending upon the results, they may order an internal scan. Alternatively, they may refer you to a specialist gynaecology unit for investigation, or if they do not think ovarian cancer is a likely cause they may ask you to return if your symptoms do not clear over a period of time.
Treatment normally involves chemotherapy and/or surgery – usually a total hysterectomy. If this is the case then supplemental bio-identical progesterone will help to counter the effects of this sudden surgical menopause.
Reducing Your Risk
Having a healthy hormone balance is essential and monitoring yourself for symptoms of oestrogen dominance, and tackling them would certainly be a good start. This article by Dame Dr Shirley Bond outlines them here and a diet that reduces other risk factors such as animal fats and refined sugar and replaces them with more plant-based foods, complex carbohydrates and fibre will also be of benefit.
National Foundation for Cancer Research Funds Novel Approach to Early Detection of Ovarian Cancer February 26, 2012Posted by patoconnor in cancer, gynecological cancer, ovarian cancer, tubal cancer, Uncategorized, uterine cancer, vaginal cancer.
Tags: cancer research, early detection, ovarian cancer, research grant
add a comment
National Foundation for Cancer Research Funds Novel Approach to Early Detection of Ovarian Cancer
Feb 23, 2012
LBUQUERQUE, N.M., Feb 23, 2012 (BUSINESS WIRE) — The National Foundation for Cancer Research has awarded a grant to Dr. Robert C. Bast, Jr. of The University of Texas MD Anderson Cancer Center to work with Senior Scientific LLC, a company owned by Manhattan Scientifics MHTX 0.00% , to apply Senior Scientifics’ technology to the early detection of ovarian cancer.
Senior Scientific has pioneered a novel technology using special magnetic sensors and magnetic nanoparticles for a highly sensitive and very specific approach to cancer detection.
The new grant, entitled “SQUID Imaging for Detection of Early Stage Ovarian Cancer,” will augment Dr. Bast’s ongoing program at The University of Texas MD Anderson Cancer Center with this emerging technology. Dr. Bast is a world leader in the early detection of ovarian cancer and was responsible for the discovery of the most accurate marker for this disease, CA-125.
The principal challenge in this grant is to overcome the problem of early detection of ovarian cancer where only 25% of ovarian cancer patients are currently detected in stage I. When the disease can be detected in Stage 1, 90% of those patients can be cured.
V. Gerald Grafe, president of Senior Scientific, said, “We are delighted with this support from the National Foundation for Cancer Research for our cooperation with Dr. Bast and The University of Texas MD Anderson Cancer Center. The focus of the grant is to combine Senior Scientifics’ highly sensitive technology, developed by our founder, Edward R. Flynn, PhD, with the expertise in cancer-markers developed at The University of Texas MD Anderson Cancer Center by Dr. Bast. Success of the program will allow us to detect ovarian cancer much earlier, leading to life-saving treatment for ovarian cancer patients.”
Dr. Flynn’s research was initially funded by the NIH, with the initial objective to be able to spot cancerous breast tumors years earlier than a mammogram can, with no radiation and high specificity and has now been applied to ovarian cancer. Dr. Flynn’s technology uses microscopic iron oxide nanoparticles, attached to known breast cancer antibodies, which specifically bind to breast cancers. The bound nanoparticles create a magnetic signal that is detected by an ultra sensitive magnetic sensor device developed by Dr. Flynn; this patented technology enables the technician to see the cancer with as few as 100,000 cells. A mammogram typically cannot detect a tumor until at least 100 million cells are present.
The new Ovarian Cancer grant triggers collaboration between Drs. Bast, Flynn & a team led by Richard S. Larson, MD, PhD, Vice Chancellor UNM Health Sciences Center in New Mexico.
About Manhattan Scientifics
Manhattan Scientifics Inc. ( http://www.mhtx.com ) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company’s actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
SOURCE: Manhattan Scientifics, Inc.